137 related articles for article (PubMed ID: 28572795)
21. Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus.
Singh NB; Yim J; Jahanbakhsh S; Sakoulas G; Rybak MJ
Diagn Microbiol Infect Dis; 2018 Aug; 91(4):363-370. PubMed ID: 29807674
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.
Mercier RC; Houlihan HH; Rybak MJ
Antimicrob Agents Chemother; 1997 Jun; 41(6):1307-12. PubMed ID: 9174189
[TBL] [Abstract][Full Text] [Related]
23. Genomic investigation and clinical correlates of the
Petersiel N; Giulieri S; Daniel DS; Fan S-H; Ersoy SC; Davis JS; Bayer AS; Howden BP; Tong SYC;
Antimicrob Agents Chemother; 2024 Jun; ():e0021824. PubMed ID: 38837393
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
[TBL] [Abstract][Full Text] [Related]
25. [Enhancement of in vitro antimicrobial activity of cefmetazole and cefotiam in combination against methicillin-susceptible and -resistant Staphylococcus aureus studied using checkerboard MIC method and disc diffusion method with discs containing both drugs].
Matsuo K; Uete T
Jpn J Antibiot; 1993 Mar; 46(3):222-33. PubMed ID: 8510319
[TBL] [Abstract][Full Text] [Related]
26. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
Vidaillac C; Leonard SN; Rybak MJ
Int J Antimicrob Agents; 2010 Jun; 35(6):527-30. PubMed ID: 20346632
[TBL] [Abstract][Full Text] [Related]
27. Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
Tarasi A; Cassone M; Monaco M; Tarasi D; Pompeo ME; Venditti M
J Chemother; 2003 Jun; 15(3):239-43. PubMed ID: 12868549
[TBL] [Abstract][Full Text] [Related]
28. Comparative activity of tedizolid and glycopeptide combination therapies for the treatment of Staphylococcus aureus infections: an in vitro and in vivo evaluation against strains with reduced susceptibility to glycopeptides.
Betts JW; Abdul Momin HF; Phee LM; Wareham DW
J Med Microbiol; 2018 Feb; 67(2):265-271. PubMed ID: 29300156
[TBL] [Abstract][Full Text] [Related]
29. Vancomycin MIC susceptibility testing of methicillin-susceptible and methicillin-resistant Staphylococcus aureus isolates: a comparison between Etest® and an automated testing method.
Bland CM; Porr WH; Davis KA; Mansell KB
South Med J; 2010 Nov; 103(11):1124-8. PubMed ID: 20890258
[TBL] [Abstract][Full Text] [Related]
30. Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals.
Nonhoff C; Denis O; Struelens MJ
Clin Microbiol Infect; 2005 Mar; 11(3):214-20. PubMed ID: 15715719
[TBL] [Abstract][Full Text] [Related]
31. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
32. In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections.
Drago L; De Vecchi E; Nicola L; Gismondo MR
BMC Infect Dis; 2007 Sep; 7():111. PubMed ID: 17888153
[TBL] [Abstract][Full Text] [Related]
33. In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci.
Huang V; Brown WJ; Rybak MJ
Antimicrob Agents Chemother; 2004 Jul; 48(7):2719-23. PubMed ID: 15215134
[TBL] [Abstract][Full Text] [Related]
34. Synergism of prenylflavonoids from Morus alba root bark against clinical MRSA isolates.
Zuo GY; Yang CX; Han J; Li YQ; Wang GC
Phytomedicine; 2018 Jan; 39():93-99. PubMed ID: 29433688
[TBL] [Abstract][Full Text] [Related]
35. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380
[TBL] [Abstract][Full Text] [Related]
36. In vitro synergy between cefepime and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis.
Lozniewski A; Lion C; Mory F; Weber M
J Antimicrob Chemother; 2001 Jan; 47(1):83-6. PubMed ID: 11152435
[TBL] [Abstract][Full Text] [Related]
37. [Combined effects of arbekacin with other antibiotics against methicillin-resistant Staphylococcus aureus. IV. Combined effects of arbekacin with cefmetazole or flomoxef].
Deguchi K; Yokota N; Koguchi M; Nakane Y; Suzuki Y; Suzuki K; Fukayama S; Ishihara R; Oda S
Jpn J Antibiot; 1992 Oct; 45(10):1312-8. PubMed ID: 1479683
[TBL] [Abstract][Full Text] [Related]
38. Vancomycin MICs and risk of complicated bacteremia by glycopeptide-susceptible Staphylococcus aureus.
Falcón R; Mateo E; Oltra R; Giménez E; Albert E; Torres I; Navarro D
Eur J Clin Microbiol Infect Dis; 2019 May; 38(5):903-912. PubMed ID: 30729396
[TBL] [Abstract][Full Text] [Related]
39. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations.
Paladino JA; Jacobs DM; Shields RK; Taylor J; Bader J; Adelman MH; Wilton GJ; Crane JK; Schentag JJ
Int J Antimicrob Agents; 2014 Dec; 44(6):557-63. PubMed ID: 25282169
[TBL] [Abstract][Full Text] [Related]
40. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002.
Robert J; Bismuth R; Jarlier V
J Antimicrob Chemother; 2006 Mar; 57(3):506-10. PubMed ID: 16410265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
